Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

TEMPISIN1234
Filter zurücksetzen
Mo., 06.10.2025

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER...
Fr., 12.09.2025

SCOTTSDALE, Ariz., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Black Rock Coffee Bar, Inc. (“Black Rock Coffee Bar”) today announced the pricing of the initial public offering of 14,705,882 shares of its Class A common stock at a price to the public of $20.00 per share. Black Rock Coffee Bar has granted the underwriters a 30-day option to purchase up to a...
Do., 04.09.2025

Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates...
Di., 02.09.2025

LIMASSOL, Cyprus, Sept. 02, 2025 (GLOBE NEWSWIRE) -- GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”), released its financial and operational results for the second quarter and first half-year ended June 30, 2025....
Di., 02.09.2025

SCOTTSDALE, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Black Rock Coffee Bar, Inc. (“Black Rock Coffee Bar”) today announced the launch of the initial public offering of 14,705,882 shares of its Class A common stock. The initial public offering price is currently expected to be between $16.00 and $18.00 per share. Black Rock Coffee Bar expects to...
Mi., 27.08.2025

Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025...
Mi., 20.08.2025

LAGUNA HILLS, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Elite Express Holding Inc. (ETS), a last-mile delivery service provider based in California, today announced the pricing of its initial public offering of 3,800,000 shares of Class A common stock at a public offering price of $4.00 per share, for gross proceeds of approximately $15.2 million...
Mo., 18.08.2025

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Black Rock Coffee Bar, Inc. (“Black Rock Coffee Bar”) today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered an...
Mo., 11.08.2025

BBOT Debuts as Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition...
Di., 29.07.2025

Company’s fourth lunar mission and fifth NASA CLPS award utilizes Firefly’s Elytra orbital vehicle and Blue Ghost lunar lander to operate two rovers and three scientific instruments Company’s fourth lunar mission and fifth NASA CLPS award utilizes Firefly’s Elytra orbital vehicle and Blue Ghost lunar lander to operate two rovers and three scientifi...
Silent Ad
Mo., 28.07.2025

CEDAR PARK, Texas, July 28, 2025 (GLOBE NEWSWIRE) -- Firefly Aerospace, a market leading space and defense technology company, today announced that it has launched the roadshow for its proposed initial public offering of 16,200,000 shares of its common stock. In addition, Firefly intends to grant the underwriters a 30-day option to purchase an ad...
Di., 22.07.2025

Largest commercial insurer in the United States releases positive comprehensive coverage for AI-enabled Heartflow Plaque Analysis to support precise diagnosis and management of patients Largest commercial insurer in the United States releases positive comprehensive coverage for AI-enabled Heartflow Plaque Analysis to support precise diagnosis and m...
Fr., 27.06.2025

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences...
Do., 26.06.2025

MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- Jefferson Capital, Inc. (“Jefferson Capital”), a leading analytically driven purchaser and manager of charged-off and insolvency consumer accounts, today announced the pricing of its underwritten initial public offering of 10,000,000 shares of common stock at an initial public offering price of $15.0...
Di., 24.06.2025

Vivoryon Therapeutics N.V. Reports Outcomeof 2025 Annual General Meeting...
Di., 17.06.2025

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress...
Mi., 11.06.2025

Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025...
Fr., 06.06.2025

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025...
Di., 27.05.2025

Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat...
Fr., 16.05.2025

LIMASSOL, Cyprus, May 16, 2025 (GLOBE NEWSWIRE) -- GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”) released its financial and operational results for the first quarter ended March 31, 2025....
Silent Ad
Di., 13.05.2025

Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meetingon June 24, 2025...
Mo., 05.05.2025

PHOENIX, May 05, 2025 (GLOBE NEWSWIRE) -- Fold Holdings, Inc. (NASDAQ: FLD) (“Fold” or the “Company”), the first publicly traded bitcoin financial services company, announces the appointment of Matthew McManus as Chief Operating Officer, effective April 21, 2025....
Di., 29.04.2025

Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update...
Do., 24.04.2025

Vivoryon Therapeutics N.V. Signs Financing Agreementfor up to EUR 15 Million...
Do., 17.04.2025

Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025...
Di., 08.04.2025

MEXICO CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Grupo Aeromexico S.A.B. de C.V. (“Aeromexico”) reports its March 2025 operational results:...
Fr., 07.03.2025

Fold now holds over 1,485 bitcoin in its corporate treasury as it builds the future of bitcoin-powered financial services Fold now holds over 1,485 bitcoin in its corporate treasury as it builds the future of bitcoin-powered financial services...
Do., 06.03.2025

Marex Group plc announces record fourth quarter and full year 2024 results...
Di., 25.02.2025

GDEV Inc. issued a clarification in respect of its previously announced one-time, nonrecurring special cash dividend of $3.31 per share....
Fr., 21.02.2025

GDEV announced a one-time, nonrecurring special cash dividend of $3.31 per share, representing a yield of approximately 20%....
Mi., 19.02.2025

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers...
Mo., 17.02.2025

Marex Group plc to Announce Fourth Quarter and Full Year 2024 Results on March 6, 2025 with an Investor Day on April 2, 2025...
Do., 13.02.2025

GDEV Inc. announces the appointment of Andrey Fadeev, GDEV's founder and CEO and a member of the Company’s Board of Directors, as Chairperson of the Board....
Do., 13.02.2025

SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the pricing of its initial public offering of 5,8...
Fr., 07.02.2025

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, tod...
Fr., 31.01.2025

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, today announced the pricing of...
Do., 30.01.2025

IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the of...
Do., 16.01.2025

Ft. Lauderdale, FL, Jan. 16, 2025 (GLOBE NEWSWIRE) -- OptimumBank is proud to announce that it will be presenting at the upcoming Sequire Investor Summit 2025. The 2025 Edition of the Sequire Investor Summit is scheduled for January 21st-23rd, 2025, at Condado Vanderbilt Hotel in San Juan, Puerto Rico, and once again promises to offer an array of...
Do., 16.01.2025

SAN DIEGO, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Beam Global, (Nasdaq: BEEM), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, announced today that Desmond Wheatley, Chief Executive Officer, will participate in the Sequire Investor Summit in San Juan, Puerto R...
Di., 14.01.2025

Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease...
Di., 10.12.2024

Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease...
Mo., 09.12.2024

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data fromVIVA-MIND Strongly Supporting Varoglutamstat’s Potential toImprove Kidney Function...
Fr., 06.12.2024

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag...
Fr., 06.12.2024

Showcases Robust Development and Commitment to Sustainable Mobility Solutions Showcases Robust Development and Commitment to Sustainable Mobility Solutions...
Mi., 04.12.2024

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024...
Do., 21.11.2024

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferen...
Do., 14.11.2024

GDEV Inc. releases its unaudited financial and operational results for the third quarter and first nine months ended September 30, 2024....
Do., 07.11.2024

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity...
Do., 07.11.2024

Marex Group plc Announces Third Quarter 2024 Results...
Sa., 26.10.2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024...